Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTCX NASDAQ:HIND NASDAQ:LYRA NASDAQ:MHUA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTCXCarmell$0.60-3.2%$1.83$0.17▼$1.27$12.54M0.514.65 million shs3,587 shsHINDVyome$5.30+5.8%$0.00$4.71▼$720.00$3.37M1.05888,404 shs83,471 shsLYRALyra Therapeutics$7.37-6.9%$6.94$3.81▼$37.50$13.02M0.1143,893 shs37,985 shsMHUAMeihua International Medical Technologies$0.40+0.5%$0.40$0.25▼$1.17$12.77M0.75195,641 shs129,925 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTCXCarmell-3.23%-27.71%-68.68%-89.47%+72.61%HINDVyome+5.79%-14.65%+529,999,900.00%+529,999,900.00%+529,999,900.00%LYRALyra Therapeutics-6.94%-2.90%+17.17%-13.60%-33.75%MHUAMeihua International Medical Technologies+0.55%+8.44%-16.86%-6.90%-46.71%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTCXCarmell$0.60-3.2%$1.83$0.17▼$1.27$12.54M0.514.65 million shs3,587 shsHINDVyome$5.30+5.8%$0.00$4.71▼$720.00$3.37M1.05888,404 shs83,471 shsLYRALyra Therapeutics$7.37-6.9%$6.94$3.81▼$37.50$13.02M0.1143,893 shs37,985 shsMHUAMeihua International Medical Technologies$0.40+0.5%$0.40$0.25▼$1.17$12.77M0.75195,641 shs129,925 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTCXCarmell-3.23%-27.71%-68.68%-89.47%+72.61%HINDVyome+5.79%-14.65%+529,999,900.00%+529,999,900.00%+529,999,900.00%LYRALyra Therapeutics-6.94%-2.90%+17.17%-13.60%-33.75%MHUAMeihua International Medical Technologies+0.55%+8.44%-16.86%-6.90%-46.71%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTCXCarmell 0.00N/AN/AN/AHINDVyome 3.00Buy$15.00183.02% UpsideLYRALyra Therapeutics 1.50Reduce$100.001,256.85% UpsideMHUAMeihua International Medical Technologies 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest HIND, LYRA, MHUA, and CTCX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025LYRALyra TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025MHUAMeihua International Medical TechnologiesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/2/2025HINDVyomeCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy10/2/2025HINDVyomeMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold ➝ Buy$15.0010/2/2025HINDVyomeMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold ➝ Buy$15.009/27/2025LYRALyra TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025MHUAMeihua International Medical TechnologiesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)8/14/2025LYRALyra TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral(Data available from 10/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTCXCarmell$32.84K381.95N/AN/A$1.07 per share0.56HINDVyome$303.09K11.77N/AN/A($34.66) per share-0.15LYRALyra Therapeutics$1.53M7.90N/AN/A$8.86 per share0.83MHUAMeihua International Medical Technologies$89.55M0.14$0.46 per share0.88$6.34 per share0.06Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTCXCarmell-$15.44MN/A0.00∞N/AN/A-217.50%-50.22%N/AHINDVyome-$7.13M-$433.08N/A∞N/A-69.71%-216.95%-69.42%N/ALYRALyra Therapeutics-$93.43M-$29.01N/AN/AN/A-5,043.64%-404.56%-60.06%11/11/2025 (Estimated)MHUAMeihua International Medical Technologies$10.84MN/A0.00∞N/AN/AN/AN/AN/ALatest HIND, LYRA, MHUA, and CTCX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025LYRALyra Therapeutics-$5.98N/AN/AN/AN/AN/A8/12/2025Q2 2025LYRALyra Therapeutics-$5.79-$5.51+$0.28-$5.51$0.18 million$0.29 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTCXCarmellN/AN/AN/AN/AN/AHINDVyomeN/AN/AN/AN/AN/ALYRALyra TherapeuticsN/AN/AN/AN/AN/AMHUAMeihua International Medical TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTCXCarmellN/A0.310.29HINDVyomeN/A2.771.97LYRALyra TherapeuticsN/A2.782.78MHUAMeihua International Medical TechnologiesN/A5.715.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTCXCarmell24.22%HINDVyome22.06%LYRALyra Therapeutics95.62%MHUAMeihua International Medical Technologies1.17%Insider OwnershipCompanyInsider OwnershipCTCXCarmell29.00%HINDVyome32.98%LYRALyra Therapeutics3.25%MHUAMeihua International Medical Technologies66.56%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTCXCarmell1420.91 million14.84 millionNot OptionableHINDVyome50673,000451,000N/ALYRALyra Therapeutics501.64 million1.59 millionOptionableMHUAMeihua International Medical Technologies62031.90 million10.67 millionNot OptionableHIND, LYRA, MHUA, and CTCX HeadlinesRecent News About These CompaniesMeihua International Medical Technologies Secures $15.2 Million Through Private PlacementOctober 14 at 5:31 PM | tipranks.comMeihua International Announces Leadership ChangesOctober 6, 2025 | theglobeandmail.comMeihua International Medical Technologies Releases Mid-2025 Financial ResultsSeptember 18, 2025 | tipranks.comLeadership Changes at Meihua International Medical TechnologiesAugust 22, 2025 | msn.comReturns On Capital Signal Tricky Times Ahead For Meihua International Medical Technologies (NASDAQ:MHUA)July 18, 2025 | finance.yahoo.comMeihua International Gains Nasdaq Capital Market Approval Amid Compliance EffortsJune 6, 2025 | tipranks.comMeihua International Medical Technologies Full Year 2024 Earnings: EPS: US$0.40 (vs US$0.49 in FY 2023)April 27, 2025 | finance.yahoo.comMeihua International Medical Technologies Co., Ltd. Reports 2024 Financial Year ResultsApril 25, 2025 | prnewswire.comMeihua International Halts Convertible Note Sales, Amends Securities AgreementJanuary 3, 2025 | tipranks.comMeihua International Medical Technologies (NASDAQ:MHUA) Is Reinvesting At Lower Rates Of ReturnDecember 23, 2024 | uk.finance.yahoo.comRemote medical interpreting is a double-edged sword in healthcare communication, researchers findNovember 6, 2024 | sciencedaily.comSDigital Medical and Artificial Intelligence Innovation Forum Held in BeijingOctober 31, 2024 | markets.businessinsider.comGlobal medical technology firm shifts some of its California manufacturing to MexicoOctober 22, 2024 | msn.comMeihua Intl Medical Techs (NASDAQ:MHUA) Stock Quotes, Forecast and News SummaryOctober 7, 2024 | benzinga.comMeihua International Medical Technologies Co., Ltd Regains Compliance with Nasdaq Minimum Bid Price RequirementOctober 7, 2024 | prnewswire.comMeihua Intl Medical Techs (NASDAQ:MHUA) Stock, Short Interest ReportOctober 4, 2024 | benzinga.comMeihua International Medical Technologies First Half 2024 Earnings: EPS: US$0.19 (vs US$0.29 in 1H 2023)September 25, 2024 | finance.yahoo.comMeihua International Medical Technologies Co., Limited Reports Unaudited 2024 First Half Financial ResultsSeptember 20, 2024 | prnewswire.comFrost & Sullivan grants the Global Medical Imaging Foundation Model Innovation Award to Hangzhou Diagens Biotechnology Co.,Ltd.September 18, 2024 | digitimes.comDMIT xPRO Launches the Medical Technology Program for Global Leaders in Collaboration with EmeritusSeptember 18, 2024 | tmcnet.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesGameStop Partying Like It’s 2021: What’s Behind Its 2025 Rebound?By Dan Schmidt | September 22, 2025Cathie Wood Buys Alibaba and Baidu: Momentum or More Value Ahead?By Gabriel Osorio-Mazilli | September 29, 2025Is Sandisk Still a Buy After 118% AI-Fueled Surge?By Gabriel Osorio-Mazilli | October 3, 2025Rocket Lab: A Space Giant Hitting New Highs—Time to Chase?By Ryan Hasson | October 9, 2025Amphenol: The Unseen Giant Behind Every Major Tech TrendBy Jeffrey Neal Johnson | October 8, 2025HIND, LYRA, MHUA, and CTCX Company DescriptionsCarmell NASDAQ:CTCX$0.60 -0.02 (-3.23%) As of 10/13/2025Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.Vyome NASDAQ:HIND$5.30 +0.29 (+5.79%) As of 10/14/2025 04:00 PM EasternReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.Lyra Therapeutics NASDAQ:LYRA$7.37 -0.55 (-6.94%) Closing price 10/14/2025 03:58 PM EasternExtended Trading$7.72 +0.35 (+4.75%) As of 08:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.Meihua International Medical Technologies NASDAQ:MHUA$0.40 +0.00 (+0.55%) Closing price 10/14/2025 03:59 PM EasternExtended Trading$0.40 0.00 (-1.07%) As of 08:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Meihua International Medical Technologies Co., Ltd. engages in the manufacture, sells, and marketing of medical consumables in the People's Republic of China. The company offers class I, II, and III disposable medical devices. Its products include non-bottled products, such as brushes and ID bracelets; and polyethylene bottled products, such as eye drop and tablet bottles, as well as electronic pumps. The company also distributes disposable medical devices sourced from other manufacturers to customers in China. In addition, it offers COVID-19 products comprising disposable medical masks. The company serves hospitals, pharmacies, medical institutions, and medical equipment companies. It also exports its products to Europe, North America, South America, Asia, Africa, and Oceania. The company was founded in 1991 and is based in Yangzhou, the People's Republic of China. Meihua International Medical Technologies Co., Ltd. operates as a subsidiary of Bright Accomplish Limited. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Healthcare Companies Insiders Are Buying NVIDIA Analysts Lift Targets: What It Means for the Stock Price Fastenal Stock Pulls Back in October—Is It Time to Buy FAST? 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Why Congress Is Buying Intuitive Surgical Ahead of Earnings D-Wave: Reevaluating the Short Seller’s Case After the Downgrade 3 Dividend Hikes That Signal Renewed Strength in 2025 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
